Antibodies

09 Jan 2018 InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
09 Jan 2018 Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
09 Jan 2018 NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
09 Jan 2018 Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
09 Jan 2018 Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
09 Jan 2018 Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
09 Jan 2018 Advanced Proteome Therapeutics and Heidelberg Pharma Progress Collaborative Program
08 Jan 2018 Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
08 Jan 2018 European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
07 Jan 2018 FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
07 Jan 2018 Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
04 Jan 2018 ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies
04 Jan 2018 Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
04 Jan 2018 Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
04 Jan 2018 Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
04 Jan 2018 Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
03 Jan 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
03 Jan 2018 Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen Coupled to the Decision to Initiate Combination Trial with ADC-1013
03 Jan 2018 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer
02 Jan 2018 Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy
02 Jan 2018 FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
02 Jan 2018 BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma
29 Dec 2017 CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia
29 Dec 2017 Biocon and Mylan's Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through their Partner Libbs
27 Dec 2017 CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top